Payment overview · 2025
General Payments
$137.43
7 reported records · 6 companies
Healthcare provider profile · identity verified
Perry J Olson, P.A.-C.
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant|Medical · DETROIT, MI · NPI 1104847847
Verified facts
What the public records show
CMS Open Payments records show Perry J Olson, P.A.-C. received $137.43 in general payments during 2025 across 7 reported records.
Salix Pharmaceuticals, a division of Bausch Health US, LLC accounted for 23.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Kerendia, Xifaxan.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Kerendia by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $32.24 | 23.5% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $30.23 | 22.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $24.18 | 17.6% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $21.33 | 15.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.55 | 11.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.90 | 10.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $137.43 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $32.24 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $30.23 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $24.18 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $21.33 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.55 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $13.90 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $13.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 39 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
39 | 11 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 249 | 85 |
| Amlodipine Besylate | Amlodipine Besylate | 212 | 68 |
| Lisinopril | Lisinopril | 151 | 56 |
| Omeprazole | Omeprazole | 87 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 79 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 79 | 30 |
| Levothyroxine Sodium | Levothyroxine Sodium | 78 | 26 |
| Metformin Hcl | Metformin Hcl | 77 | 28 |
| Losartan Potassium | Losartan Potassium | 71 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 69 | 21 |
| Gabapentin | Gabapentin | 69 | 17 |
| Ibuprofen | Ibuprofen | 67 | 19 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 65 | 18 |
| Ezetimibe | Ezetimibe | 61 | 17 |
| Alprazolam | Alprazolam | 59 | 15 |
| Pantoprazole Sodium | Pantoprazole Sodium | 52 | 17 |
| Famotidine | Famotidine | 51 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 48 | 14 |
| Trulicity | Dulaglutide | 47 | 16 |
| Furosemide | Furosemide | 46 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 44 | 12 |
| Simvastatin | Simvastatin | 44 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 43 | 19 |
| Glimepiride | Glimepiride | 43 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 42 | 14 |
| Atenolol | Atenolol | 40 | 12 |
| Carvedilol | Carvedilol | 39 | 12 |
| Eliquis | Apixaban | 39 | 11 |
| Allopurinol | Allopurinol | 38 | 11 |
| Spironolactone | Spironolactone | 37 | suppressed |
| Jardiance | Empagliflozin | 35 | 14 |
| Tramadol Hcl | Tramadol Hcl | 35 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 33 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 33 | suppressed |
| Potassium Chloride | Potassium Chloride | 31 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 30 | 12 |
| Azithromycin | Azithromycin | 30 | 26 |
| Buspirone Hcl | Buspirone Hcl | 29 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 29 | suppressed |
| Januvia | Sitagliptin Phosphate | 28 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 27 | suppressed |
| Prednisone | Prednisone | 27 | 18 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 25 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 25 | suppressed |
| Ketoconazole | Ketoconazole | 23 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | suppressed |
| Diazepam | Diazepam | 21 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 21 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 11 |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Ozempic | Semaglutide | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Aripiprazole Odt | Aripiprazole | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Cartia Xt | Diltiazem Hcl | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Minoxidil | Minoxidil | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Xifaxan | Rifaximin | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 11 | suppressed |
| Febuxostat | Febuxostat | 11 | suppressed |
| Kerendia | Finerenone | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Meloxicam | Meloxicam | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Westab Plus | Pnv,calcium 72/Iron/Folic Acid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $137.43 · 7 records | Salix Pharmaceuticals, a division of Bausch Health US, LLC | Auvelity, BREZTRI, ELIQUIS, Kerendia, NURTEC ODT, The Cologuard Plus Collection Kit, XIFAXAN | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error